Real-world results may differ from clinical trial results for some drugs approved to treat gastrointestinal cancers, according to research published in Clinical Oncology.
Researchers found that EGFR inhibitors and sorafenib performed as expected in the real world, but some chemotherapy drugs did not.
For this study, researchers used the Systemic Anti-Cancer Therapy (SACT) dataset, which includes information on all patients receiving chemotherapy in England. The researchers noted that SACT data has largely gone unpublished, “despite concerns that real-world effectiveness of medicines may be inferior to that seen in clinical trials.”
Read More: https://www.cancertherapyadvisor.com/home/cancer-topics/gastrointestinal-cancers/gastrointestinal-cancer-drugs-real-world-clinical-trial-data/